Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2006

01-06-2006 | Clinical trial

Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer

Authors: Brenda W. Cooper, Tomas Radivoyevitch, Beth A. Overmoyer, Robert R. Shenk, Huong T. Pham, Judith R. Samuels, Margaret P. Parry, Paula Silverman

Published in: Breast Cancer Research and Treatment | Issue 3/2006

Login to get access
Metadata
Title
Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer
Authors
Brenda W. Cooper
Tomas Radivoyevitch
Beth A. Overmoyer
Robert R. Shenk
Huong T. Pham
Judith R. Samuels
Margaret P. Parry
Paula Silverman
Publication date
01-06-2006
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2006
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-005-9125-4

Other articles of this Issue 3/2006

Breast Cancer Research and Treatment 3/2006 Go to the issue

Preclinical study

Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells

OriginalPaper

Serum selenium measurements in women with early-stage breast cancer with and without chemotherapy-induced ovarian failure

Epidemiology

Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women

Clinical trial

The “Sentinel Chain”: a new concept for prediction of axillary node status in breast cancer patients

Preclinical Study

Genome-Wide Analysis for Loss of Heterozygosity in Primary and Recurrent Phyllodes Tumor and Fibroadenoma of Breast using Single Nucleotide Polymorphism Arrays

Clinical trial

Patients with preoperatively ultrasonically uninvolved axillary lymph nodes: a distinct subgroup of early breast cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits